StockNews.com initiated coverage on shares of Pulmatrix (NASDAQ:PULM – Free Report) in a research note issued to investors on Saturday morning. The firm issued a hold rating on the biotechnology company’s stock.
Pulmatrix Stock Performance
NASDAQ:PULM opened at $1.93 on Friday. The company has a market capitalization of $7.04 million, a price-to-earnings ratio of -0.80 and a beta of 1.00. Pulmatrix has a one year low of $1.55 and a one year high of $2.75. The stock has a 50-day simple moving average of $2.11 and a 200 day simple moving average of $1.97.
Pulmatrix (NASDAQ:PULM – Get Free Report) last issued its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.87) EPS for the quarter. Pulmatrix had a negative return on equity of 46.86% and a negative net margin of 95.18%. The firm had revenue of $1.55 million during the quarter.
About Pulmatrix
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Read More
- Five stocks we like better than Pulmatrix
- Pros And Cons Of Monthly Dividend Stocks
- Matador Resources Insiders Keep Buying Its Stock, Should You?
- How to Invest in Biotech Stocks
- Oracle Can Turn the Magnificent 7 Into 8: Here’s Why
- What is a buyback in stocks? A comprehensive guide for investors
- Palantir Stock Is Up 14% on S&P 500 News: Is It Time to Buy?
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
